Speaker illustration

Doctor Mika Lehto

Helsinki University Hospital, Helsinki (Finland)

Member of:

European Society of Cardiology
European Heart Rythm Association

Quo vadis, the leading arrhythmia? Projecting the prevalence of atrial fibrillation up to 2070

Event: ESC Congress 2024

Topic: Prevalence and Incidence of Atrial Fibrillation

Session: Risk factors for atrial fibrillation and stroke prediction

Thumbnail

Time-in-therapeutic-range defined warfarin and standard dose direct oral anticoagulants in atrial fibrillation: Ischemic stroke, intracranial hemorrhage and death in a nationwide registry study

Event: ESC Congress 2023

Topic: Oral Anticoagulation

Session: Atrial fibrillation and high-rate episodes: stroke prediction and prevention

Thumbnail

How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study.

Event: EHRA 2023

Topic: Oral Anticoagulation

Session: Atrial Fibrillation - Round 1 - Stroke - OAC

Thumbnail

Prevalence of atrial fibrillation - a comprehensive nationwide analysis in Finland

Event: ESC Congress 2022

Topic: Prevalence and Incidence of Atrial Fibrillation

Session: Insights from atrial fibrillation registries and observational studies

Thumbnail

Incidence of atrial fibrillation. A comprehensive nationwide analysis in Finland.

Event: ESC Congress 2021 - The Digital Experience

Topic: Prevalence and Incidence of Atrial Fibrillation

Session: Congress committee e-posters choice in arrhythmias and device therapy

Thumbnail

All you want to know about the arrhythmia: A comprehensive, nationwide registry study of atrial fibrillation in Finland

Event: EHRA 2021

Topic: Public Health and Health Economics, Other

Session: ePoster session

Thumbnail